Posted by Balancing biosafety with multifunctionality remains a critical challenge in biopatch development, impeding clinical translation. This study introduces a minimally invasive myocardial patch fabricated entirely from FDA-approved components, integrating piezoelectric property and a sustained release of miRNA agomir. Briefly, the piezoelectric small intestinal submucosa (SIS) serves as the matrix for the in situ growth of β-cyclodextrin metal-organic framework (β-CD-MOF). Cholesterol-modified miR-210 Agomir (miRNA mimic) is efficiently loaded into cyclodextrin cavities through host-guest interactions. Flexibility and water-triggered adhesion properties, bestowed by a poly (sodium thioctate) (PST) coating on the rim, allow the dry SIS-Patch to fold into a catheter-deliverable tube for minimally invasive implantation. In rat myocardial infarction models, the Ago-Patch achieved sustained miR-210 Agomir release, effectively downregulating target gene expression. Simultaneously, the piezoelectric SIS converts mechanical energy in vivo into electrical pulses, activating related signaling pathway. Synergistic gene-electrical therapy improved cardiac function, increasing ejection fraction by 14.0% and fractional shortening by 10.4%, while attenuating left ventricular remodeling and fibrosis. The Ago-Patch’s dual-action mechanism offers a safe, multifunctional solution for cardiac repair.
Tingting Ye, Yaping Li, Xiaolin Li, et al. (2025) A Piezoelectric and Suture-Free Cardiac Patch Assembled by all FDA-approved Materials Achieves a Minimally Invasive Gene Therapy. advanced Functional Material https://doi.org/10.1002/adfm.202425399